Chemical Immunology and the Birth of a New Industry

Much of the science of immunology is concerned with two classes of molecules – 1) antigens that stimulate the immune system to produce adaptive antibodies, and 2) antibodies with weak chemical reactivity (Abs) that target toxic antigens for removal. But Darwinian evolution also created antibodies with more powerful chemical reactivity: 

catalytic antibodies (catabodies) and irreversible antibodies (IrAbs) that eliminate disease-causing proteins 1000x more powerfully than regular antibodies (Abs) 

A new synthetic biology platform harnesses this chemical power by making possible the selection of the catabodies and IrAbs in monoclonal form, and the ability to induce their synthesis using engineered vaccines (E-vaccines). Catabodies and IrAbs can be selected to target any protein that causes disease:

• aging diseases - Alzheimer’s, TTR Amyloidosis, others
• infectious diseases - HIV, Staph Aureus, COVID-19 and the next pandemic, others
• cancer
• autoimmune disease
• others

In this video, renowned industry leaders discuss the science, commercial potential, and societal impact of this transformational technology:

• What is the role of catabody and IrAb therapeutics in curing the most intractable diseases?
• Will catabody-inducing E-vaccines be deployed to prevent infections by the most virulent microbes?   
• What scientific and commercial challenges remain on the road ahead?
• How long before catabodies, IrAbs and E-vaccines displace and surpass the $140B+ monoclonal antibody and $70B+ vaccine markets?
• ...and more!

Panelists:

Sudhir Paul, Ph.D., CSO & Co-Founder of Covalent Bioscience

Discoverer of naturally occurring catabodies, inventor of synbio catabody discovery platform, over 200 publications

https://covalentbioscience.com/about-us/   

Anthony Rees, Professor Emeritus and Honorary DSc, University of Bath, UK

Antibody/catabody expert – wrote the book on antibodies: “The Antibody Molecule – from Anti-Toxins to Therapeutic Antibodies” 

http://reesconsultingab.com/   

Joel Buxbaum, MD, Professor Emeritus, Scripps Research

Expert on Alzheimers, TTR amyloidosis and other aging diseases 

https://www.scripps.edu/faculty/buxbaum/   

Seth Pincus, MD, Professor Antibody Biology and Medicine, Montana State University

Infectious disease expert and authority on vaccines and antibodies 

https://chemistry.montana.edu/directory/2077781/seth-pincus   

Richard Massey, Ph.D., CEO & Co-Founder of Covalent Bioscience

Biotech serial entrepreneur and expert on commercial opportunities of catabodies, E-vaccines, and IrAbs

https://covalentbioscience.com/about-us/   

Host and Moderator:

William Kazman, Founding Partner of GeneWorx Capital

MIT engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact

https://www.geneworxcapital.com/team